Примери за използване на Routine laboratory на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Routine Laboratory Investigations.
Performing routine laboratory tests.
In general, there were no clinically important influences of Atacand on routine laboratory variables.
Includes elevations collected as part of routine laboratory monitoring(see text below) 1 See section 4.3.
Alkaline Phosphatase(ALP) is used as the detection reagent in many routine laboratory assays.
During routine laboratory monitoring in the 12 week controlled phase, elevation in ALT or AST≥ 3 x.
Includes observations collected as part of routine laboratory monitoring.
Routine laboratory assessments detected elevated haemoglobin above ULN in 9.7% of patients receiving axitinib.
Apart from this,sodium levels should be determined during routine laboratory examination.
Routine laboratory tests, such as determination of prothrombin time and platelet count, are frequently abnormal and point to a state which is hypocoagulable.
Includes observations collected as part of routine laboratory monitoring. 5 Includes fatal cases.
During routine laboratory monitoring in the tocilizumab all exposure population, 1% of patients had a decrease in platelet count to≤ 50× 103/µL without associated bleeding events.
The UV-VIS spectrophotometer DR6000 delivers top performance for both routine laboratory tasks and demanding photometry applications.
During routine laboratory monitoring in the tocilizumab all exposure population, elevation in ALT or AST≥ 3xULN occurred in 3.7% and< 1% of patients, respectively.
The results of the testing should be confirmed at the earliest opportunity in a routine laboratory with a standard HIV test.
HlV infection is diagnosed with rather now routine laboratory tests for which there are criteria for diagnosis established by the manufacturer… FDA.
Frequency category derived from laboratory values collected as part of routine laboratory monitoring in clinical trials.
Sometimes the diagnosis is limited to routine laboratory tests, but sometimes doctors recommend an immunoassay to determine the body's immune status as accurately as possible.
Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory parameters revealed no medically important differences.
Platelets During routine laboratory monitoring in the 12 week controlled phase, 3% of patients in the placebo group and 1% in the tocilizumab group had a decrease in platelet count to≤ 100 x 103/µl.
Frequency category derived from laboratory values collected as part of routine laboratory monitoring in clinical trials 2 Frequency category derived from post-marketing data.
Platelets During routine laboratory monitoring in the RoActemra 6 month clinical trial SC-I, none of the patients on the SC weekly dose had a decrease in platelet count to≤50× 103/ μL.
During the double-blind controlled period, the incidence of indirect bilirubingreater than the upper limit of normal, collected as a routine laboratory parameter, is 6.2% in patients treated with 8 mg/kg RoActemra+ DMARD.
While adhering to all safety rules,competently perform routine laboratory tasks in the chemistry laboratory using the instrumentation for measurement and analysis that is commonly available.
During routine laboratory monitoring in the 12 week controlled phase, a decrease in neutrophil counts below 1 x 109/l occurred in 7% of patients in the tocilizumab group, and no decreases in the placebo group.
Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory and lipid parameters(see section 5.1) revealed no medically important differences.
During routine laboratory monitoring in the RoActemra 6 month controlled clinical trial SC-I, a decrease in neutrophil count below 1× 109/L occurred in 2.9% of patients on the subcutaneous weekly dose.
During routine laboratory monitoring in the 12 week controlled phase(study WA18221), 13.4% and 33.3% of patients experienced a post-baseline elevation of their LDL-cholesterol value to≥ 130 mg/dL.
During routine laboratory monitoring in the RoActemra 12 month controlled clinical trial, one patient(1%, 1/100) in the RoActemra subcutaneous weekly group had a single transient occurence of decrease in platelet count to< 100× 103/ μL without associated bleeding events.
Routine laboratory tests may commonly reveal changes to liver functions(hyperbilirubinaemia) as well as changes in blood count(e.g. Coombs'(direct) test positive), increased alanine aminotransferase, increased aspartate aminotransferase, increased blood lactate dehydrogenase.